Picture Berlin Partner Top News CareSyntax Raises $61m for Bio Cheese 650x100px

Document › Details

H. Lundbeck A/S. (5/13/24). "Press Release: Maria Alfaiate Appointed New Executive Vice President Commercial and Corporate Strategy at Lundbeck".

	Organisation	H. Lundbeck A/S
	Group	Lundbeck (Group)
	Organisation 2	Bayer (Group)
	Product	pharmaceutical
	Product 2	CNS drug (neurological drug)
	Person	Alfaiate, Maria (Lundbeck 202408– EVP Commercial + Corporate Strategy before Bayer + AstraZeneca + MSD/Merck)
	Person 2	van Zyl, Charl (Lundbeck 202309– CEO before UCB + Jado Technologies + Novartis + Lilly)

H. Lundbeck A/S (Lundbeck) today announced the appointment of Maria Alfaiate to the newly established role of EVP, Commercial and Corporate Strategy. Maria will join Lundbeck on 1 August 2024 and will be part of the Executive Management team.

Maria Alfaiate will be responsible for strengthening corporate strategic functions and enhancing global marketing efforts. Her focus will be on optimizing Lundbeck’s ability to capitalize on both present and future opportunities.

Maria brings significant experience from the life science and pharmaceutical sectors globally. Her expertise in developing strategic plans and executing programs to deliver state-of-the-art solutions for patients across diverse markets will play a pivotal role in shaping Lundbeck’s future growth.

“I am delighted to welcome Maria to Lundbeck. Her impressive track record in strategic commercial leadership is a great asset to our company. Her ability to design and execute innovative plans, coupled with her deep understanding of global markets, will undoubtedly strengthen our corporate strategic functions, and support the success of therapies as they become available to patients,” says President and CEO Charl van Zyl.

“Embarking on this new journey, I am fueled by the possibilities ahead and the opportunity to be impactful. I am joining a remarkable group of individuals devoted to helping patients suffering from neurological or psychiatric conditions. The vision of making a positive contribution to people and society resonates tremendously at a personal level,” says Maria Alfaiate.

Maria joins Lundbeck from Bayer where she recently served as Senior Vice President and Global Head of New Products Commercialization and Portfolio Strategy. Prior to this, Maria has held positions at AstraZeneca and MSD/ Merck, in global teams but also at country level.

Maria is of Portuguese nationality and holds a Master of Clinical Psychology from Universidade de Coimbra, Portugal.

Contacts

Thomas Mikkel Mortensen Palle Holm Olesen
Media Relations Lead, Corp. Communication Vice President, Investor Relations
THMR@lundbeck.com PALO@lundbeck.com
+45 30 83 30 24 +45 30 83 24 26

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.

Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

H. Lundbeck A/S

Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311
info@lundbeck.com

Record changed: 2024-08-11